Prestige Consumer Healthcare

Prestige Consumer Healthcare is a holding company. Through its subsidiaries, the company develops, manufactures, markets, sells and distributes over-the-counter (OTC) healthcare products to mass merchandisers and drug, food, dollar, convenience, and club stores in North America (the U.S. and Canada) and in Australia and certain other international markets. The company's portfolio of OTC Healthcare products includes, among others, DenTek oral care products, Monistat women's health products, Nix lice treatment products, Chloraseptic sore throat treatments, Clear Eyes eye care products, Compound W wart treatments, Luden's throat drops, BC and Goody's pain relievers and Debrox earwax remover.
  • TickerPBH
  • ISINUS74112D1019
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
PBH Prestige Consum... (Health Care)

Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Fourth Quarte...

Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Fourth Quarter and Year-End Earnings Results TARRYTOWN, N.Y., April 08, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2021 fourth quarter and year-end earnings release on Thursday, May 6, 2021 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate via phone listeners calling from the U.S. and Canada may dial 844-233-9440, or 574-990-1016 internationally, using the conferen...

PBH Prestige Consum... (Health Care)

PRESTIGE CONSUMER reduced its risk exposure resulting in an upgrade to...

PRESTIGE CONSUMER (US), a company active in the Drug Retailers industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 3 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date March 16, 2021, the closing price was USD 46.88 and its potential was estimated at USD 49.22.

PBH Prestige Consum... (Health Care)

Prestige Consumer Healthcare Inc: 1 director sold after exercising opt...

A director at Prestige Consumer Healthcare Inc sold after exercising options/sold 12,264 shares at 42.637USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is rest...

 PRESS RELEASE
PBH Prestige Consum... (Health Care)

Prestige Consumer Healthcare Inc. Announces Upsize and Pricing of $600...

Prestige Consumer Healthcare Inc. Announces Upsize and Pricing of $600 Million Senior Notes TARRYTOWN, N.Y., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), has priced an upsized offering of $600 million in aggregate principal amount of 3.750% senior notes due 2031 (the “notes”) in a private offering. The sale of the notes is expected to be completed on or about March 1, 2021, subject to customary closing conditions. The notes will be senior unsecure...

 PRESS RELEASE
PBH Prestige Consum... (Health Care)

Prestige Consumer Healthcare Inc. Announces Offering of $500 Million S...

Prestige Consumer Healthcare Inc. Announces Offering of $500 Million Senior Notes TARRYTOWN, N.Y., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), intends to offer, subject to market and other conditions, up to $500 million in aggregate principal amount of new senior notes due 2031 (the “notes”) in a private offering. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic su...

 PRESS RELEASE
PBH Prestige Consum... (Health Care)

Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Fourth Quarte...

Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Fourth Quarter and Year-End Earnings Results TARRYTOWN, N.Y., April 08, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2021 fourth quarter and year-end earnings release on Thursday, May 6, 2021 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate via phone listeners calling from the U.S. and Canada may dial 844-233-9440, or 574-990-1016 internationally, using the conferen...

PBH Prestige Consum... (Health Care)

Prestige Consumer Healthcare Inc: 1 director sold after exercising opt...

A director at Prestige Consumer Healthcare Inc sold after exercising options/sold 12,264 shares at 42.637USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is rest...

 PRESS RELEASE
PBH Prestige Consum... (Health Care)

Prestige Consumer Healthcare Inc. Announces Upsize and Pricing of $600...

Prestige Consumer Healthcare Inc. Announces Upsize and Pricing of $600 Million Senior Notes TARRYTOWN, N.Y., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), has priced an upsized offering of $600 million in aggregate principal amount of 3.750% senior notes due 2031 (the “notes”) in a private offering. The sale of the notes is expected to be completed on or about March 1, 2021, subject to customary closing conditions. The notes will be senior unsecure...

 PRESS RELEASE
PBH Prestige Consum... (Health Care)

Prestige Consumer Healthcare Inc. Announces Offering of $500 Million S...

Prestige Consumer Healthcare Inc. Announces Offering of $500 Million Senior Notes TARRYTOWN, N.Y., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), intends to offer, subject to market and other conditions, up to $500 million in aggregate principal amount of new senior notes due 2031 (the “notes”) in a private offering. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic su...

 PRESS RELEASE
PBH Prestige Consum... (Health Care)

Prestige Consumer Healthcare Inc. Reports Fiscal 2021 Third Quarter Re...

Prestige Consumer Healthcare Inc. Reports Fiscal 2021 Third Quarter Results Revenue was $238.8 Million in Third Quarter Fiscal 2021Diluted EPS of $0.81 in Third Quarter Fiscal 2021Net Cash Provided by Operating Activities for First Nine Months of Fiscal 2021 Increased 10% to $176.5 millionRaising Full-Year Fiscal 2021 Outlook for Revenue and Earnings Per Share TARRYTOWN, N.Y., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2020. “Our third quarter and year-...

Valens Research
  • Valens Research
PBH Prestige Consum... (Health Care)

PBH - Embedded Expectations Analysis - 2018 08 02

Prestige Brands Holdings, Inc. (PBH:USA) is currently trading near historical lows relative to UAFRS-based (Uniform) Earnings, with a 13.4x Uniform P/E. At these levels, the market has bearish expectations for the firm, driven by concerns surrounding their dependence on growth through acquisition and a ballooning balance sheet Specifically, the market appears concerned about PBH's slow organic growth, and subsequent reliance on M&A to maintain growth. Additionally, the market may lack confidence in PBH's ability to find acquisition targets given the substantial amount of debt already on thei...

Please Change Name Raven A Burnett
  • Please Change Name Raven A Burnett
PBH Prestige Consum... (Health Care)

Prestige Brands, Inc.: Loan Covenant Quality Snapshot

CORPORATES ISSUER IN-DEPTH 21 July 2017 Facility Size; Maturity: Term B-4: $1,427m; 26 Jan 2024 (but springing maturity to 91 days before the 2021 Notes maturity date or 2024 Notes maturity if either has > $100m of debt outstanding) Incremental: $350m plus amount so consolidated first lien net leverage ratio ≤ 4.0x Pricing: Term B: Eurocurrency rate + 2.75% / ABR + 1.75% initiall

PBH Prestige Consum... (Health Care)

PRESTIGE CONSUMER reduced its risk exposure resulting in an upgrade to...

PRESTIGE CONSUMER (US), a company active in the Drug Retailers industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 3 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date March 16, 2021, the closing price was USD 46.88 and its potential was estimated at USD 49.22.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch